GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Three-Drug attack on stomach cancer shows promise
Disease control Recruiting nowThis study is testing whether adding a new targeted drug called Zolbetuximab to standard chemotherapy improves survival for people with advanced stomach or esophageal cancer. It's for patients whose cancer has a specific protein marker called CLDN18.2 and whose disease has progre…
Matched conditions: GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for tough stomach cancers: trial tests Dual-Attack drug combo
Disease control Recruiting nowThis study is testing a new combination of two immunotherapy drugs, called AK109 and AK104, for people with advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination, given with or without standard chemotherapy, can help control the cancer after…
Matched conditions: GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC